These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23719582)

  • 1. Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial.
    Rademakers SE; Hoogsteen IJ; Rijken PF; Oosterwijk E; Terhaard CH; Doornaert PA; Langendijk JA; van den Ende P; Takes R; De Bree R; van der Kogel AJ; Bussink J; Kaanders JH
    Radiother Oncol; 2013 Sep; 108(3):517-22. PubMed ID: 23719582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: results of the accelerated radiotherapy with carbogen breathing and nicotinamide phase III randomized trial.
    Rademakers SE; Hoogsteen IJ; Rijken PF; Terhaard CH; Doornaert PA; Langendijk JA; van den Ende P; van der Kogel AJ; Bussink J; Kaanders JH
    Head Neck; 2015 Feb; 37(2):171-6. PubMed ID: 24347430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial.
    Janssens GO; van Bockel LW; Doornaert PA; Bijl HP; van den Ende P; de Jong MA; van den Broek GB; Verbist BM; Terhaard CH; Span PN; Kaanders JH
    Eur J Cancer; 2014 Apr; 50(6):1112-9. PubMed ID: 24424106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.
    Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Takes RP; de Bree R; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
    Clin Cancer Res; 2014 Mar; 20(5):1345-54. PubMed ID: 24452791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.
    Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Marres HA; de Bree R; van der Kogel AJ; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
    J Clin Oncol; 2012 May; 30(15):1777-83. PubMed ID: 22508814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
    Jonathan RA; Wijffels KI; Peeters W; de Wilde PC; Marres HA; Merkx MA; Oosterwijk E; van der Kogel AJ; Kaanders JH
    Radiother Oncol; 2006 Jun; 79(3):288-97. PubMed ID: 16730088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.
    Kaanders JH; Wijffels KI; Marres HA; Ljungkvist AS; Pop LA; van den Hoogen FJ; de Wilde PC; Bussink J; Raleigh JA; van der Kogel AJ
    Cancer Res; 2002 Dec; 62(23):7066-74. PubMed ID: 12460928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
    Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
    Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial.
    Nijkamp MM; Span PN; Terhaard CH; Doornaert PA; Langendijk JA; van den Ende PL; de Jong M; van der Kogel AJ; Bussink J; Kaanders JH
    Eur J Cancer; 2013 Oct; 49(15):3202-9. PubMed ID: 23867129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
    Hoskin PJ; Rojas AM; Phillips H; Saunders MI
    Cancer; 2005 Jun; 103(11):2287-97. PubMed ID: 15834926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
    Klatte T; Seligson DB; Rao JY; Yu H; de Martino M; Kawaoka K; Wong SG; Belldegrun AS; Pantuck AJ
    Cancer; 2009 Apr; 115(7):1448-58. PubMed ID: 19195047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
    Kaanders JH; Pop LA; Marres HA; Liefers J; van den Hoogen FJ; van Daal WA; van der Kogel AJ
    Radiother Oncol; 1998 Aug; 48(2):115-22. PubMed ID: 9783882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
    Janssens GO; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Pop LA; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):532-8. PubMed ID: 21300447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON.
    Hoskin PJ; Sibtain A; Daley FM; Wilson GD
    Br J Cancer; 2003 Oct; 89(7):1290-7. PubMed ID: 14520462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
    Hoogsteen IJ; Pop LA; Marres HA; Merkx MA; van den Hoogen FJ; van der Kogel AJ; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):83-9. PubMed ID: 16213107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
    Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
    Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
    Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
    Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.
    Bui MH; Visapaa H; Seligson D; Kim H; Han KR; Huang Y; Horvath S; Stanbridge EJ; Palotie A; Figlin RA; Belldegrun AS
    J Urol; 2004 Jun; 171(6 Pt 1):2461-6. PubMed ID: 15126876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society.
    Janssens GO; Langendijk JA; Terhaard CH; Doornaert PA; van den Ende P; de Jong MA; Takes RP; Span PN; Kaanders JH
    Radiother Oncol; 2016 May; 119(2):213-20. PubMed ID: 27165613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).
    Bernier J; Denekamp J; Rojas A; Minatel E; Horiot J; Hamers H; Antognoni P; Dahl O; Richaud P; van Glabbeke M; Piérart M
    Radiother Oncol; 2000 May; 55(2):111-9. PubMed ID: 10799722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.